Recombinant Human JAK2 (JH2 Domain) (E596A, V617F, W659A, W777A, F794H) Protein, His-tagged
Cat.No. : | JAK2-32H |
Product Overview : | Recombinant human JAK2 (Janus Kinase 2) encompassing amino acids 536-812, containing the pseudo-kinase domain JH2 with mutations E596A, V617F, W659A, W777A, and F794H. This construct contains a C-terminal His-tag (6xHis). The protein was affinity purified. |
- Specification
- Gene Information
- Related Products
- Download
Description : | This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. |
Source : | Insect cell |
Species : | Human |
Tag : | His |
Form : | Aqueous buffer solution |
Molecular Mass : | 33 kDa |
Protein length : | 535-812 |
Storage : | At least 6 months at –80 centigrade. |
Storage Buffer : | 20 mM Tris-HCI pH 8.5, 0.5 mM TCEP and 10% glycerol. |
Gene Name : | JAK2 Janus kinase 2 [ Homo sapiens (human) ] |
Official Symbol : | JAK2 |
Synonyms : | JAK2; Janus kinase 2; JTK10; tyrosine-protein kinase JAK2; JAK-2; Janus kinase 2 (a protein tyrosine kinase); EC 2.7.10.2; jak; jh1 |
Gene ID : | 3717 |
mRNA Refseq : | NM_004972 |
Protein Refseq : | NP_004963 |
MIM : | 147796 |
UniProt ID : | O60674 |
Products Types
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewQuick response from customer service.
Product performed as expected.
Satisfied with product quality.
Q&As (7)
Ask a questionJAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.
Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.
JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.
JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.
JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.
Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.
Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).
Ask a Question for All JAK2 Products
Required fields are marked with *
My Review for All JAK2 Products
Required fields are marked with *
Inquiry Basket